172 related articles for article (PubMed ID: 31287239)
1. Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
Dumas PY; Bérard E; Bréal C; Dulucq S; Réa D; Nicolini F; Forcade E; Dufossée M; Pasquet JM; Turcq B; Bidet A; Milpied N; Déchanet-Merville J; Lafarge X; Etienne G; Mahon FX;
Cancer Med; 2019 Sep; 8(11):4976-4985. PubMed ID: 31287239
[TBL] [Abstract][Full Text] [Related]
2. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
3. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Marin D; Gabriel IH; Ahmad S; Foroni L; de Lavallade H; Clark R; O'Brien S; Sergeant R; Hedgley C; Milojkovic D; Khorashad JS; Bua M; Alsuliman A; Khoder A; Stringaris K; Cooper N; Davis J; Goldman JM; Apperley JF; Rezvani K
Leukemia; 2012 Feb; 26(2):296-302. PubMed ID: 21844874
[TBL] [Abstract][Full Text] [Related]
4. [Chronic myeloid leukemia and NK cell immunity].
Ureshino H; Shindo T; Tanaka H; Kimura S
Rinsho Ketsueki; 2017; 58(4):381-388. PubMed ID: 28484170
[TBL] [Abstract][Full Text] [Related]
5. KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.
Yeung DT; Tang C; Vidovic L; White DL; Branford S; Hughes TP; Yong AS
Blood; 2015 Dec; 126(25):2720-3. PubMed ID: 26500342
[TBL] [Abstract][Full Text] [Related]
6. Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.
La Nasa G; Caocci G; Littera R; Atzeni S; Vacca A; Mulas O; Langiu M; Greco M; Orrù S; Orrù N; Floris A; Carcassi C
Exp Hematol; 2013 May; 41(5):424-31. PubMed ID: 23380384
[TBL] [Abstract][Full Text] [Related]
7. Allelic Polymorphisms of
Ureshino H; Shindo T; Kojima H; Kusunoki Y; Miyazaki Y; Tanaka H; Saji H; Kawaguchi A; Kimura S
Cancer Immunol Res; 2018 Jun; 6(6):745-754. PubMed ID: 29695383
[TBL] [Abstract][Full Text] [Related]
8. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
[TBL] [Abstract][Full Text] [Related]
9. Allelic polymorphisms of
Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
11.
Ureshino H; Shindo T; Tanaka H; Saji H; Kimura S
Mol Cancer Ther; 2021 Jan; 20(1):142-149. PubMed ID: 33082274
[TBL] [Abstract][Full Text] [Related]
12. Certain Killer Immunoglobulin-Like Receptor (KIR)/KIR HLA Class I Ligand Genotypes Influence Natural Killer Antitumor Activity in Myelogenous Leukemia but Not in Acute Lymphoblastic Leukemia: A Case Control Leukemia Association Study.
Varbanova VP; Mihailova S; Naumova E; Mihaylova AP
Turk J Haematol; 2019 Nov; 36(4):238-246. PubMed ID: 31337191
[TBL] [Abstract][Full Text] [Related]
13. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.
Rea D; Henry G; Khaznadar Z; Etienne G; Guilhot F; Nicolini F; Guilhot J; Rousselot P; Huguet F; Legros L; Gardembas M; Dubruille V; Guerci-Bresler A; Charbonnier A; Maloisel F; Ianotto JC; Villemagne B; Mahon FX; Moins-Teisserenc H; Dulphy N; Toubert A
Haematologica; 2017 Aug; 102(8):1368-1377. PubMed ID: 28522576
[TBL] [Abstract][Full Text] [Related]
14. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Ilander M; Olsson-Strömberg U; Schlums H; Guilhot J; Brück O; Lähteenmäki H; Kasanen T; Koskenvesa P; Söderlund S; Höglund M; Markevärn B; Själander A; Lotfi K; Dreimane A; Lübking A; Holm E; Björeman M; Lehmann S; Stenke L; Ohm L; Gedde-Dahl T; Majeed W; Ehrencrona H; Koskela S; Saussele S; Mahon FX; Porkka K; Hjorth-Hansen H; Bryceson YT; Richter J; Mustjoki S
Leukemia; 2017 May; 31(5):1108-1116. PubMed ID: 27890936
[TBL] [Abstract][Full Text] [Related]
15. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
Front Immunol; 2018; 9():2587. PubMed ID: 30487792
[TBL] [Abstract][Full Text] [Related]
16. Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.
Breccia M; Foà R
Curr Oncol Rep; 2018 Mar; 20(3):23. PubMed ID: 29511948
[TBL] [Abstract][Full Text] [Related]
17. Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.
Bhalla S; Tremblay D; Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):488-494. PubMed ID: 27406834
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
Ross DM; Pagani IS; Shanmuganathan N; Kok CH; Seymour JF; Mills AK; Filshie RJ; Arthur CK; Dang P; Saunders VA; Braley J; Yong AS; Yeung DT; White DL; Grigg AP; Schwarer AP; Branford S; Hughes TP;
Leukemia; 2018 Dec; 32(12):2572-2579. PubMed ID: 30315232
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.
Nicolini FE; Dulucq S; Boureau L; Cony-Makhoul P; Charbonnier A; Escoffre-Barbe M; Rigal-Huguet F; Coiteux V; Varet B; Dubruille V; Lenain P; Rousselot P; Rea D; Guerci-Bresler A; Legros L; Liu J; Gardembas M; Ianotto JC; Turlure P; Johnson-Ansah H; Martiniuc J; Jardel H; Joly B; Zunic P; Henni T; Villemagne B; Berger MG; Cayssials E; Guilhot F; Larosa F; Guilhot J; Etienne G; Mahon FX
Clin Cancer Res; 2019 Nov; 25(22):6606-6613. PubMed ID: 31292142
[TBL] [Abstract][Full Text] [Related]
20. Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.
Stella S; Tirró E; Massimino M; Vitale SR; Russo S; Pennisi MS; Puma A; Romano C; DI Gregorio S; Innao V; Stagno F; DI Raimondo F; Musolino C; Manzella L
In Vivo; 2019; 33(5):1593-1598. PubMed ID: 31471409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
